BioSpace News Archive

Biostar Pharma, Inc. is pleased to announce that, after having in-depth discussions with the FDA through pre-IND meetings, the FDA has approved the IND of a phase 2/3 clinical trial with seamless protocol design for the company’s core product utidelone injectable in patients with locally advanced or metastatic non-small cell lung cancer.

Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping dexlansoprazole 30 mg capsules, a generic version of Takeda’s Dexilant®.

Hemab Therapeutics announced it will present data from preclinical research of HMB-001 in Factor VII deficiency at the upcoming International Society on Thrombosis and Haemostasis 2023 Congress, June 24 – 28, in Montreal.

Cantex Pharmaceuticals, Inc. announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.

NLS Pharmaceutics Ltd. announced plans to showcase its global strategic R&D progress and platform.

Femasys Inc. announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors.

Satsuma Pharmaceuticals, Inc., and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s 65th Annual Scientific Meeting.

Nemaura Medical, Inc. announces it will exhibit and provide product demonstrations of its non-invasive daily-wear glucose sensor platform at the 83rd Scientific Sessions of the American Diabetes Association.

Integer Holdings Corporation announced that Joe Dziedzic, President and Chief Executive Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development, and Investor Relations, will participate in Citi’s 2023 European Healthcare Conference, which will be held at the Citigroup Centre, 33 Canada Square, London, England, beginning at 8:00 a.m. British Summer Time, on Tuesday, June 20, 2023.

Bionomics Limited, a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, announced that it will present at the following upcoming investor conferences in June.